Ma · Asian journal of andrology 2021 · Randomized controlled animal study · n=24

N-acetylcysteine maintains penile length and erectile function in bilateral cavernous nerve crush rat model by reducing penile fibrosis.

Cited 5 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Preclinical animal experiment (bilateral cavernous nerve crush model in rats)

PubMed 32394901 · doi:10.4103/aja.aja_17_20 · record verified 2026-08-27

What was done

Twenty-four male rats were randomly allocated into three groups: control, bilateral cavernous nerve crush (BCNC), and BCNC treated with N-acetylcysteine (NAC). Rats received daily intragastric gavage of either NAC or saline for 4 weeks. Researchers evaluated initial and end penile length, erectile function via the intracavernosal pressure to mean arterial pressure (ICP/MAP) ratio, and tissue histology and molecular markers (including eNOS, α-SMA, glutathione, GPx1, HIF-1α, TGF-β1, collagens I/III/IV, malonaldehyde, and lysine oxidase).

What was found

The abstract does not provide exact numerical values or effect sizes. It reports that compared to the untreated BCNC group, the BCNC + NAC group had significantly greater penile length, ICP/MAP ratios, smooth muscle-to-collagen ratios, and expressions of eNOS, α-SMA, glutathione, and GPx1 (all P < 0.05). In addition, NAC treatment significantly reduced levels of HIF-1α, TGF-β1, collagens I, III, and IV, malonaldehyde, and lysine oxidase (all P < 0.05).

Why it matters

Penile shortening and erectile dysfunction are frequent sequelae of radical prostatectomy. This study provides preclinical evidence that antioxidant and antifibrotic therapy with NAC may mitigate structural and functional penile deterioration following cavernous nerve injury.

Limits

Findings are limited to an acute crush injury model in a small rodent cohort (n = 24 total across three groups). Specific quantitative measurements and baseline values are omitted in the abstract, and whether these antifibrotic effects translate to human clinical outcomes following prostatectomy is unknown.

Cited by